Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Life Science Investing
Innovation Pharmaceuticals Concludes Successful Phase 2a Trial of Kevetrin for Ovarian Cancer Pharmaceutical Investing
pSivida’s Second Phase 3 Study for Durasert™ Three-year Treatment for Posterior Segment Uveitis Pharmaceutical Investing
Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2 Pharmaceutical Investing
Novartis receives FDA approval for Cosentyx label update to include moderate-to-severe scalp psoriasis Pharmaceutical Investing
Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 Pharmaceutical Investing
Cellectar Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma Biotech Investing
Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results Biotech Investing
